drugset / Trial / NCT03097341
Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of xisomab 3G3 in healthy adult subjects.
Timeline
- Start
- 2017-06-05
- Primary completion
- 2018-01-16
- Completion
- 2018-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xisomab 3G3 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | Xisomab 3G3 | Unknown | 0.5 mg/kg | Intravenous |
| Subject | Xisomab 3G3 | Unknown | 2 mg/kg | Intravenous |
| Subject | Xisomab 3G3 | Unknown | 5 mg/kg | Intravenous |